

RESPIRONICS INC  
Form 8-K  
February 11, 2004

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

**FORM 8-K**

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): February 10, 2004

**RESPIRONICS, INC.**

(Exact name of Registrant as specified in its charter)

Delaware

000-16723

25-1304989

(State or Other Jurisdiction of  
Incorporation)

(Commission File  
Number)

(I.R.S. Employer  
Identification Number)

1010 Murry Ridge Lane  
Murrysville, Pennsylvania

15668-8525

(Address of Principal Executive Offices)

(Zip Code)

724-387-5200

(Registrant's telephone number, including area code)

**TABLE OF CONTENTS**

	<b>Page</b>
Item 12. DISCLOSURE OF RESULTS OF OPERATIONS AND FINANCIAL CONDITION	2
SIGNATURES	3
INDEX TO EXHIBITS	4

---

---

**Table of Contents**

**Item 12. DISCLOSURE OF RESULTS OF OPERATIONS AND FINANCIAL CONDITION.**

On February 10, 2004, Respiroics, Inc. issued a press release announcing that it received a warning letter from the U.S. Food & Drug Administration regarding its Carlsbad, CA manufacturing facility. In that press release, Respiroics, Inc. also reported that it will not be changing its financial outlook or guidance for fiscal year 2004 based on the warning letter. A copy of the press release is attached hereto as Exhibit 99.

**Exhibits**

99 Press release, dated February 10, 2004, issued by Respiroics, Inc.

**Table of Contents**

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

RESPIRONICS, INC.

By: /s/ Daniel J. Bevevino

---

Daniel J. Bevevino  
Vice President, and Chief Financial and  
Principal Accounting Officer

Dated: February 10, 2004

**Table of Contents**

INDEX TO EXHIBITS

<b>Exhibit No.</b>	<b>Description</b>
99	Press release, dated February 10, 2004, issued by Respironics, Inc.